Cingulate Inc.
CING
We are a biopharmaceutical company using our proprietary Precision Timed Release TM ( PTR TM ) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial foc…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$29M
▼ -35.6% YoY
Op. Margin
–
ROIC
-106.06%
▼ -2.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$21M
▲ +6.7% YoY
Op. Cash Flow (TTM)
-$21M
▲ +6.5% YoY
Net Debt
-$22M
Net Cash Position
Cash & Equiv.
$28M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with CING
Cingulate (CING) in two numbers
Questions about Cingulate
Does Cingulate (CING) pay a dividend?
No. Cingulate (CING) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 13 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CING's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CING
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.